Stock PGEN PRECIGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Precigen, Inc.

Equities

PGEN

US74017N1054

Delayed Nasdaq
Other stock markets
 03:47:42 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.405 USD -0.35% Intraday chart for Precigen, Inc. +1.81% +4.85%
Apr. 24 Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy CI
Mar. 25 North American Morning Briefing : Tech in Focus on -2- DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
AQ
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
PR
Precigen Reports Full Year 2023 Financial Results and Business Updates
AQ
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
PR
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PR
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
PR
Precigen to Participate in the Stifel 2023 Healthcare Conference
PR
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
PR
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
AQ
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
PR
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
PR
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
AQ
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR
PRECIGEN, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Precigen Reports First Quarter 2023 Financial Results and Business Updates
AQ
PRECIGEN, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PGEN Stock
  4. News Precigen, Inc.
  5. Press Releases